RT Journal Article
SR Electronic
T1 The role of aldosterone receptor antagonists in the management of heart failure: An update
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP 631
OP 639
DO 10.3949/ccjm.79a.12014
VO 79
IS 9
A1 Vijaiganesh Nagarajan
A1 Mohammed Chamsi-Pasha
A1 W. H. Wilson Tang
YR 2012
UL http://www.ccjm.org/content/79/9/631.abstract
AB The aldosterone receptor antagonists (ARAs) spironolactone (Aldactone) and eplerenone (Inspra) have become part of standard medical therapy for heart failure, having shown clinical efficacy in randomized trials in patients with advanced symptomatic systolic heart failure, postinfarction heart failure with cardiac dysfunction, and systolic heart failure with mild symptoms. The benefits include a lower rate of death. Yet to be answered is whether the two drugs are clinically equivalent; another question is whether they may benefit everyone with symptomatic heart failure, including diastolic heart failure.